Clinical trial · Interventional
Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses
Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses: a Phase II Multicenter Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with locoregional cancer of nasal cavity and paranasal sinuses are candidate for this study. All the eligible patients receive three cycles of induction chemotherapy (docetaxel 60mg/m2+cisplatin 60mg/m2+5-FU2.5g/m2,civ48h, q3w) followed by concurrent two cycles of cisplatin (80mg/m2,q3w) with curative intensity modulated radiotherapy. Besides, camrelizumab (200mg) is administrated every three weeks for a total of 11 cycles since the first day of induction chemotherapy. We aim to evaluate the three years failure free survival of these patients by the combination of camrelizumab with curative radiotherapy and chemotherapy.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Camrelizumab | — | UNRESOLVED | — |
| Concurrent Chemotherapy | — | UNRESOLVED | — |
| Induction Chemotherapy | — | UNRESOLVED | — |
| Intensity Modulated Radiotherapy | — | UNRESOLVED | — |
| Nasal Cavity Cancer | Malignant Nasal Cavity Neoplasm | ALIAS | 0.90 |
| Paranasal Sinus Cancer | Malignant Paranasal Sinus Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| camrelizumab | Drug | Camrelizumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- camrelizumab group
- interventionNames
- Drug: camrelizumab
Primary outcomes (1)
- measure
- 3-year failure free survival
- timeFrame
- 3-year
- description
- time from the randomization to the first treatment failure or death
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * histologically confirmed squamous cancer of nasal cavity and paranasal sinuses * T4bN0-3M0 (AJCC8th) or unresectable lymph nodes or refusal of surgery * KPS≥70 * NE≥ 1.5×10E9/L, HGB ≥ 100g/L and PLT ≥100×10E9/L * ALT≤ 1.5 upper limit of normal (ULN), AST≤ 1.5ULN and bilirubin ≤ 1.5ULN * creatinine clearance rate ≥ 60 ml/min (calculated by Cockcroft-Gault) Exclusion Criteria: * older than 65 or younger than 18 * HBsAg (+) and HBV DNA \>1×10E3 copiers /mL * HCV (+) * HIV (+) * autoimmune diseases * interstitial lung diseases * had other cancers before
References
Publications (0)
Data not yet available